Two-day low-dose dexamethasone suppression test more accurate than overnight 1-mg in women taking oral contraceptives

被引:3
|
作者
Carton, Tiphaine [1 ]
Mathieu, Elise [2 ]
Wolff, Fleur [2 ]
Bouziotis, Jason [3 ]
Corvilain, Bernard [1 ]
Driessens, Natacha [1 ]
机构
[1] Univ Libre Bruxelles ULB, Clin Univ Bruxelles Hop Erasme, Dept Endocrinol, Route Lennik 808, B-1070 Brussels, Belgium
[2] Univ Libre Bruxelles ULB, Dept Clin Chem, Lab Hosp Univ Bruxelles LHUB ULB, Brussels, Belgium
[3] Univ Libre Bruxelles ULB, Clin Univ Bruxelles Hop Erasme, Serv Rech Biomed, Brussels, Belgium
关键词
Cushing' s syndrome; dexamethasone suppression test; false positive; oral contraception; CORTISOL-BINDING GLOBULIN; URINARY FREE CORTISOL; SALIVARY CORTISOL; CUSHINGS-SYNDROME; SERUM; DIAGNOSIS; MORTALITY;
D O I
10.1002/edm2.255
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Late-night salivary cortisol (LSaC) and 24-h urinary free cortisol measurement, and overnight 1-mg dexamethasone suppression test (1 mg-DST) are the first-line screening tests recommended for Cushing's syndrome. Through elevations in the level of cortisol-binding globulin, oral contraceptive agents lead to increases in the total plasma cortisol concentration, yielding false-positive 1 mg-DST results. Objective To compare the accuracy of the overnight 1-mg DST and two-day low-dose DST (2d-DST) in female volunteers taking combined oestrogen-progestin oral contraceptives (COCs). Methods This prospective study enrolled 30 healthy participants. Their plasma cortisol response levels were compared after the 1-mg DST and 2d-DST and classified into three categories: normal (<= 50 nmol/L), doubtful (51-138 nmol/L) and abnormal (>138 nmol/L). Salivary cortisol was also measured at late night and after the DSTs. Results Following the 1-mg DST and 2d-DST, the plasma cortisol concentrations decreased to a median of 69 nmol/L and 37 nmol/L, respectively (p < 0.001). A statistically significant higher proportion of unclear or abnormal results were observed after the 1-mg DST (63%) than after the 2d-DST (27%) (p = 0.004). None of the values were >138 nmol/L after the 2d-DST, while 11% of them were abnormal after the 1-mg DST (p = 0.25). No LSaC value was abnormal. Conclusion Our results suggest that, when late-night salivary cortisol is not available, the 2d-DST could be a better screening option than the 1-mg DST for women taking oral contraceptive agents who are reluctant to stop them. This finding requires confirmation in those with a suspicion of hypercortisolism.
引用
收藏
页数:7
相关论文
共 7 条
  • [1] The influence of oral contraceptives on overnight 1 mg dexamethasone suppression test
    Vastbinder, M.
    Kuindersma, M.
    Mulder, A. H.
    Schuijt, M. P.
    Mudde, A. H.
    NETHERLANDS JOURNAL OF MEDICINE, 2016, 74 (04): : 158 - 161
  • [2] Comparison of overnight and 48h low-dose dexamethasone suppression tests in volunteers using oral contraceptives
    Carton, Tiphaine
    Mathieu, Elise
    Wolff, Fleur
    Corvilain, Bernard
    Driessens, Natacha
    ACTA CLINICA BELGICA, 2018, 73 : 15 - 16
  • [3] Low-Dose and Standard Overnight and Low Dose-Two Day Dexamethasone Suppression Tests in Patients with Mild and/or Episodic Hypercortisolism
    Mojtahedzadeh, Mona
    Shaesteh, Nesyah
    Haykani, Mastaneh
    Tran, Jennifer L. A.
    Mangubat, Michael
    Shahinian, Hraya K.
    Nachnani, Rahul
    Zopey, Mohan
    Saidian, Jason
    Thomas, Antolice
    Lee, Martin L.
    McCutcheon, Ian E.
    Friedman, Theodore C.
    HORMONE AND METABOLIC RESEARCH, 2018, 50 (06) : 453 - 461
  • [4] Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women
    Anzai, Yuzuru
    Heger-Mahn, Doris
    Schellschmidt, Ilka
    Marr, Joachim
    CONTRACEPTION, 2012, 86 (01) : 28 - 34
  • [5] The safety and tolerability of AR101, an oral immunotherapy (OIT) pharmaceutical formulation for peanut allergy, after more than 1 year of treatment: results from an ongoing phase 2b clinical trial (ARC002), including low-dose (300 mg/day) and high-dose (2000 mg/day) maintenance regimens
    Rachid, R. A.
    Bird, J. A.
    Spergel, J. M.
    Jones, S. M.
    Assa'ad, A. H.
    Vickery, B.
    Wang, J.
    Leonard, S. A.
    Laubach, S. S.
    Kim, E. H.
    Davis, B. P.
    Welch, M. J.
    Heimall, J.
    Cianferoni, A.
    MacGinnitie, A. J.
    Crestani, E.
    Bennett, S.
    Elfont, R. M.
    Burks, A. W.
    ALLERGY, 2016, 71 : 105 - 105
  • [6] Comparison of effectiveness and tolerability of two oral low-dose formulations containing 1 mg of 17 beta-estradiol and either dydrogesterone or norethisterone acetate applied as continuous combined hormonal therapy in peri- and postmenopausal women
    Paszkowski, Tomasz
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2006, 5 (06): : 367 - 373
  • [7] A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 μg ethinylestradio1/75 μg gestodene (Meliane) and 30 μg ethinylestradio1/75 μg gestodene (Gynera®)
    Taneepanichskul, S
    Kriengsinyot, R
    Jaisamrarn, U
    CONTRACEPTION, 2002, 66 (06) : 407 - 409